• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 3. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Recent Advances in the Application of 1-Bromo-2-(difluoromethoxy)benzene (CAS: 175278-33-8) in Chemical Biology and Pharmaceutical Research

1-Bromo-2-(difluoromethoxy)benzene (CAS: 175278-33-8) has emerged as a versatile building block in medicinal chemistry and drug discovery, particularly in the synthesis of bioactive molecules with improved pharmacokinetic properties. Recent studies highlight its utility as a key intermediate in the development of novel pharmaceuticals, owing to the unique electronic and steric properties imparted by the difluoromethoxy group. This aromatic compound has been increasingly employed in cross-coupling reactions, nucleophilic substitutions, and as a precursor for more complex molecular architectures.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's effectiveness in Suzuki-Miyaura cross-coupling reactions for creating biaryl structures with enhanced metabolic stability. Researchers found that the difluoromethoxy group significantly improved the compound's lipophilicity and membrane permeability compared to traditional methoxy analogs, while maintaining favorable solubility profiles. These characteristics make derivatives of 175278-33-8 particularly valuable in CNS drug development where blood-brain barrier penetration is crucial.

In pharmaceutical applications, 1-Bromo-2-(difluoromethoxy)benzene has shown promise as a precursor for kinase inhibitors. A recent patent application (WO2023057892) describes its use in synthesizing novel JAK3 inhibitors with reduced off-target effects. The difluoromethoxy modification was found to decrease oxidative metabolism in hepatic microsomes, potentially leading to drugs with improved safety profiles and longer half-lives. This represents a significant advancement in the treatment of autoimmune diseases and hematologic malignancies.

The compound's unique properties have also found applications in PET radiopharmaceutical development. Research published in ACS Medicinal Chemistry Letters (2023) detailed its use in synthesizing 18F-labeled analogs for neuroimaging. The difluoromethoxy group serves as an isostere for traditional radiolabeled groups while providing superior in vivo stability and target specificity. This innovation could lead to more accurate diagnostic tools for neurodegenerative diseases.

From a synthetic chemistry perspective, recent methodological improvements have enhanced the accessibility of 175278-33-8. A 2024 Organic Process Research & Development paper described an optimized large-scale synthesis route with improved yield (78%) and reduced environmental impact through solvent recovery systems. These process improvements are critical for meeting the growing demand for this intermediate in pharmaceutical manufacturing.

Looking forward, the unique properties of 1-Bromo-2-(difluoromethoxy)benzene continue to inspire novel applications. Current research directions include its incorporation into PROTAC molecules (proteolysis targeting chimeras) and as a building block for covalent inhibitors targeting cysteine residues. The compound's versatility and the growing understanding of fluorine's role in medicinal chemistry suggest it will remain an important tool in drug discovery for years to come.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)